Literature DB >> 27346296

How should hyperferritinaemia be investigated and managed?

Sim Y Ong1, Amanda J Nicoll2, Martin B Delatycki3.   

Abstract

Hyperferritinaemia is commonly found in clinical practice. In assessing the cause of hyperferritinaemia, it is important to identify if there is true iron overload or not as hyperferritinaemia may be seen in other conditions such as excess alcohol intake, inflammation and non-alcoholic fatty liver disease. Assessment of whether the serum ferritin level is elevated or not should take into account body mass index, gender and age. This review article provides an overview of the different causes of hyperferritinaemia, differentiating those due to iron overload from those not due to iron overload, and provides an algorithm for clinicians to use in clinical practice to carry out appropriate investigations and management.
Copyright © 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol liver disease; Erythrocytapheresis; Haemochromatosis; Hyperferritinaemia; Non-alcoholic fatty liver disease; Phlebotomy

Mesh:

Substances:

Year:  2016        PMID: 27346296     DOI: 10.1016/j.ejim.2016.05.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  3 in total

1.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

2.  Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism.

Authors:  Lars Stechemesser; Sebastian K Eder; Andrej Wagner; Wolfgang Patsch; Alexandra Feldman; Michael Strasser; Simon Auer; David Niederseer; Ursula Huber-Schönauer; Bernhard Paulweber; Stephan Zandanell; Sandra Ruhaltinger; Daniel Weghuber; Elisabeth Haschke-Becher; Christoph Grabmer; Eva Rohde; Christian Datz; Thomas K Felder; Elmar Aigner
Journal:  Mol Metab       Date:  2016-10-31       Impact factor: 7.422

3.  Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome.

Authors:  Hiroki Hosoi; Kazuo Hatanaka; Shogo Murata; Toshiki Mushino; Kodai Kuriyama; Akinori Nishikawa; Nobuyoshi Hanaoka; Shinobu Tamura; Hideki Nakakuma; Takashi Sonoki
Journal:  Hematol Rep       Date:  2018-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.